GLP-1受体激动剂在多囊卵巢综合征病理生理机制中的作用研究进展  

Research Progress in Role of GLP-1 Receptor Agonists in Pathophysiology of Polycystic Ovary Syndrome

作　　者：熊川浩 张雅慧 林毅[1] 丁晓颖[1] XIONG Chuanhao;ZHANG Yahui;LIN Yi;DING Xiaoying(Department of Endocrinology,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China)

机构地区：[1]上海交通大学医学院附属第一人民医院内分泌科,上海200080

出　　处：《医学综述》2023年第9期1809-1813,1819,共6页Medical Recapitulate

基　　金：上海申康医院发展中心临床三年行动计划(SHDC2020CR1016B);上海交通大学“交大之星”医工滚动支持项目(YG2019GD05)。

摘　　要：多囊卵巢综合征(PCOS)是育龄女性常见且具有高度临床异质性的生殖内分泌紊乱性疾病。近年PCOS的发病率呈逐年升高趋势,其代谢生殖障碍的病理生理机制与胰岛素抵抗、高雄激素血症、肠道微生态失衡等相关。胰高血糖素样肽-1(GLP-1)可改善PCOS患者体质量、胰岛素抵抗、高雄激素血症以及生殖功能紊乱,因此,GLP-1受体激动剂在PCOS的发生发展和临床应用中受到广泛关注。深入研究GLP-1受体激动剂在PCOS病理生理机制中的具体作用,可以为PCOS患者的治疗提供新思路。Polycystic ovary syndrome(PCOS)is a common and highly heterogeneous disease of reproductive endocrine disorder in women of childbearing age.In recent years,the incidence of PCOS has been increasing significantly.The pathophysiological mechanism of its metabolic reproductive disorder is related to insulin resistance,hyperandrogenemia and intestinal microecological imbalance.Since glucagon-like peptide-1(GLP-1)can improve body weight,insulin resistance,hyperandrogenemia and reproductive dysfunction in PCOS patients,its receptor agonists have gained wide attention in the development and clinical application of PCOS.An in-depth study of the specific role of GLP-1 receptor agonists in the pathophysiological mechanism of PCOS can provide new ideas for the treatment of PCOS patients.

关 键 词：多囊卵巢综合征 胰高血糖素样肽-1受体激动剂 代谢紊乱 病理生理机制 

分 类 号：R711.75[医药卫生—妇产科学]